Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma
DOI: https://doi.org/10.2147/OTT.S365506
IF: 4
2022-06-14
OncoTargets and Therapy
Abstract:Weitao Yao, 1 Xinhui Du, 1 Jiaqiang Wang, 1 Xin Wang, 1 Peng Zhang, 1 Xiaohui Niu 2 1 Bone and Soft Department, The Affiliated Cancer Hospital of Zheng Zhou University, He Nan Cancer Hospital, Zheng Zhou City, 450000, People's Republic of China; 2 Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, Beijing, 100035, People's Republic of China Correspondence: Weitao Yao, Bone and Soft Department, The Affiliated Cancer Hospital of Zheng Zhou University, He Nan Cancer Hospital, 127 Dong Ming Road, Zheng Zhou City, 450000, People's Republic of China, Email Xiaohui Niu, Department of Orthopedic Oncology Surgery, Beijing Ji Shui Tan Hospital, Peking University, No. 31 Xin Jie Kou Dong Jie, Xi Cheng District, Beijing, 100035, People's Republic of China, Email Objective: To analyze the effectiveness of the long-term (> 12 months) administration of anlotinib as a monotherapy or combined therapy in patients with advanced sarcomas. Methods: A retrospective analysis was conducted of patients with advanced sarcomas with measurable target lesions since 2018. Twenty-two of the patients had taken anlotinib regularly for > 12 months. The patients' general information and the drug's clinical efficacy and toxicity data were collected and statistically analyzed using RECIST 1.1 to measure the target lesions and tumor PFS time as the main endpoints. We used a swimmer plot to observe the drug's efficacy and duration, and employed a waterfall plot to express the best treatment effect. Results: The study included 14 male and 8 female patients, ranging in age from 14 to 75 (mean: 44.82) years. The primary diseases included alveolar soft part sarcoma, synovial sarcoma, leiomyosarcoma, and others. The metastasis sites were the lungs in fifteen cases, lymph nodes in four cases, and multiple sites in three cases. Fourteen patients had previously undergone chemotherapy. The current therapy protocol was oral anlotinib alone for nine cases, combination chemotherapy for nine cases, and combination immunotherapy (anti-PD-1) for four cases. The highest clinical efficacy was complete remission (CR) in four (18.18%) cases, partial response (PR) in five (22.73%) cases, and stable disease in 13 (59.09%) cases, with an odds ratio of response of 40.91%. The mean PFS for the CR, PR, and stable disease groups was 16.50, 14.50, and 29.31 months, respectively (p < 0.05). The main adverse effects included hand-foot syndrome, hypertension, and leukopenia. Conclusion: Anlotinib monotherapy or combination therapy can be more effective and safer for certain advanced sarcomas, with more extended maintenance and acceptable side effects. Clinical efficacy at the CR and PR levels might predict the long-term PFS in certain advanced sarcomas. Keywords: anlotinib, advanced sarcoma, targeted therapy, immunotherapy, clinical efficacy Bone and soft tissue sarcomas (STS) are a group of malignant tumors derived from mesenchymal tissue and are characterized by high heterogeneity, complicated subtypes, high malignancy, and few available therapeutic methods. Moreover, most sarcomas are prone to metastasis through blood vessels to vital organs such as the lungs. 1 The treatment of sarcoma is mainly based on extensive surgical resection, supplemented by perioperative radiotherapy, chemotherapy, and other treatments. 2–5 For localized tumors, the 5-year survival rate can reach 70%–80%; however, advanced and metastatic sarcomas have a 5-year survival rate below 20%. 5 The prognosis for patients with sarcomas remains poor, with a median overall survival (OS) of slightly more than 1 year. Therefore, exploring new methods for treating advanced sarcoma is a hot topic and challenging research area. Angiogenesis plays an essential role in tumor growth and metastasis, and blocking this pathway is a strategy that has been successfully employed in clinically treating cancer. 6–8 Receptor tyrosine kinases are among the most promising therapeutic targets and can be used to modulate cell proliferation, growth, angiogenesis, and metastasis in a wide range of cancers. 8–12 Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptors 2 and 3, fibroblast growth factor receptors 1–4, platelet-derived growth factor receptors α and β, c‐Kit, and Ret, 13 thereby exerting inhibitory effects on tumor growth and angiogenesis. A Phase I study of anlotinib by Sun et al 14 demonstrated promising antitumor potential against STS. A multicenter, Phase II study by Chi et al (NCT01878448) 15 investigated single‐agent anlotinib in 166 patients -Abstract Truncated-
oncology,biotechnology & applied microbiology